James Kihara, the Principal Accounting Officer of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), has recently engaged in transactions involving the company's stock, according to the latest SEC filings. On April 8, 2024, Kihara sold a total of 1,790 shares of common stock at an average price of $17.87, amounting to over $31,987 in total value.
The sales were conducted in multiple transactions with prices ranging from $17.7267 to $17.87. These transactions were mandatory sales made to cover withholding taxes and tax-related items in connection with the vesting of restricted stock units, as per the company's requirements and in compliance with Rule 10b5-1(c)(1)(i)(B) under the Exchange Act.
In addition to the sales, Kihara also acquired shares through the exercise of restricted stock units on April 5 and April 7. However, the filings indicate that these acquisitions did not involve any monetary transaction, as each restricted stock unit represents a contingent right to receive one share of Acadia Pharmaceuticals' common stock. The total number of shares acquired through these exercises was not disclosed in the monetary transaction totals.
Following these transactions, Kihara's ownership in the company has adjusted accordingly. Investors and shareholders often monitor such filings to gain insight into the actions of a company's executives, as these can sometimes be indicative of their confidence in the company's future performance.
Acadia Pharmaceuticals Inc., based in San Diego, California, specializes in the development of pharmaceutical preparations and has been a notable name in the life sciences sector.
InvestingPro Insights
Amidst the recent transactions by Acadia Pharmaceuticals Inc.'s (NASDAQ:ACAD) Principal Accounting Officer, James Kihara, investors may find it beneficial to consider the financial health and market performance of the company. According to InvestingPro data, Acadia Pharmaceuticals has a market capitalization of approximately $2.99 billion. Despite challenging market conditions, the company has reported significant revenue growth, with a 40.45% increase over the last twelve months as of Q1 2023, and an even more impressive quarterly revenue growth of 69.27% in Q1 2023.
However, it's not all positive news, as the company's P/E ratio stands at -48.37, reflecting investor concerns about profitability. This aligns with one of the InvestingPro Tips which indicates that Acadia Pharmaceuticals has not been profitable over the last twelve months. Yet, the same set of InvestingPro Tips provides a potential silver lining: the company holds more cash than debt on its balance sheet, and net income is expected to grow this year, suggesting a possible turnaround.
Investors considering Acadia Pharmaceuticals should note that the stock is trading near its 52-week low and the RSI suggests the stock is in oversold territory, which may appeal to value-oriented investors seeking entry points. For those looking to delve deeper into the company’s prospects, InvestingPro offers additional insights, including a total of 11 InvestingPro Tips, which can be accessed by following the link to: https://www.investing.com/pro/ACAD. To get an even more comprehensive analysis, use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.